BioCentury | Nov 5, 2020
Deals

Merck adds ROR1 to its pipeline, rewards VelosBio’s investors with $2.8B takeout

...the ADC developer that Gilead Sciences Inc. (NASDAQ:GILD) acquired this year for $21 billion.Arix and Sofinnova Ventures...
BioCentury | Jul 8, 2020
Finance

VelosBio jumps on megaround bandwagon with $137M series B

...Management Company, as well as existing investors Arix Bioscience plc (LSE:ARIX), Decheng Capital, Pappas Capital, Sofinnova Ventures...
BioCentury | Mar 21, 2020
Product Development

Under duress, biotechs will have to make hard decisions for patients and themselves about which trials to run

...check for changes to their IRB process and position on initiating new studies. According to Sofinnova Ventures’...
BioCentury | Dec 14, 2018
Financial News

Checkmate raises $22M as Krieg hands off CEO role

...president and CEO. New investor Decheng Capital led the round, with participation from existing investors Sofinnova Ventures...
BioCentury | Dec 13, 2018
Financial News

Checkmate raises $22M as Krieg hands off CEO role

...and CEO. New investor Decheng Capital led Wednesday’s financing round, with participation from existing investors Sofinnova Ventures...
BioCentury | Dec 7, 2018
Financial News

Angina gene therapy company XyloCor raises $17M series A round

...Inc. (Philadelphia, Pa.) raised $17 million Dec. 6 in a series A round led by Sofinnova Ventures...
BioCentury | Dec 6, 2018
Financial News

Angina gene therapy company XyloCor raises $17M series A round

...XyloCor Therapeutics Inc. (Philadelphia, Pa.) raised $17 million in a series A round led by Sofinnova Ventures...
BioCentury | Nov 30, 2018
Emerging Company Profile

Afyx: Mucosal drug delivery

...University of Sheffield Corporate partners: N/A Number of employees: 11 Funds raised: $20 million Investors: Sofinnova Ventures...
BioCentury | Nov 16, 2018
Financial News

Hillhouse, Quan lead $93M series B for immuno-oncology play NextCure

...as well as existing investors Canaan Partners, Lilly Asia Ventures, OrbiMed Advisors, Pfizer Inc. (NYSE:PFE), Sofinnova Ventures...
BioCentury | Nov 13, 2018
Financial News

Hillhouse, Quan lead $93M series B for immuno-oncology play NextCure

...as well as existing investors Canaan Partners, Lilly Asia Ventures, OrbiMed Advisors, Pfizer Inc. (NYSE:PFE), Sofinnova Ventures...
Items per page:
1 - 10 of 378
BioCentury | Nov 5, 2020
Deals

Merck adds ROR1 to its pipeline, rewards VelosBio’s investors with $2.8B takeout

...the ADC developer that Gilead Sciences Inc. (NASDAQ:GILD) acquired this year for $21 billion.Arix and Sofinnova Ventures...
BioCentury | Jul 8, 2020
Finance

VelosBio jumps on megaround bandwagon with $137M series B

...Management Company, as well as existing investors Arix Bioscience plc (LSE:ARIX), Decheng Capital, Pappas Capital, Sofinnova Ventures...
BioCentury | Mar 21, 2020
Product Development

Under duress, biotechs will have to make hard decisions for patients and themselves about which trials to run

...check for changes to their IRB process and position on initiating new studies. According to Sofinnova Ventures’...
BioCentury | Dec 14, 2018
Financial News

Checkmate raises $22M as Krieg hands off CEO role

...president and CEO. New investor Decheng Capital led the round, with participation from existing investors Sofinnova Ventures...
BioCentury | Dec 13, 2018
Financial News

Checkmate raises $22M as Krieg hands off CEO role

...and CEO. New investor Decheng Capital led Wednesday’s financing round, with participation from existing investors Sofinnova Ventures...
BioCentury | Dec 7, 2018
Financial News

Angina gene therapy company XyloCor raises $17M series A round

...Inc. (Philadelphia, Pa.) raised $17 million Dec. 6 in a series A round led by Sofinnova Ventures...
BioCentury | Dec 6, 2018
Financial News

Angina gene therapy company XyloCor raises $17M series A round

...XyloCor Therapeutics Inc. (Philadelphia, Pa.) raised $17 million in a series A round led by Sofinnova Ventures...
BioCentury | Nov 30, 2018
Emerging Company Profile

Afyx: Mucosal drug delivery

...University of Sheffield Corporate partners: N/A Number of employees: 11 Funds raised: $20 million Investors: Sofinnova Ventures...
BioCentury | Nov 16, 2018
Financial News

Hillhouse, Quan lead $93M series B for immuno-oncology play NextCure

...as well as existing investors Canaan Partners, Lilly Asia Ventures, OrbiMed Advisors, Pfizer Inc. (NYSE:PFE), Sofinnova Ventures...
BioCentury | Nov 13, 2018
Financial News

Hillhouse, Quan lead $93M series B for immuno-oncology play NextCure

...as well as existing investors Canaan Partners, Lilly Asia Ventures, OrbiMed Advisors, Pfizer Inc. (NYSE:PFE), Sofinnova Ventures...
Items per page:
1 - 10 of 378